Florida Gastroenterological Society
Florida Gastroenterological Society
Monthly Archives: November 2019

Gilead DAAs safe, effective for adults with HCV, severe renal impairment

The FDA approved changes to the product labels for direct-acting antivirals Harvoni, Epclusa, and Vosevi to include new efficacy andREAD MORE ›

Posted in News

Prevalence of advanced polyps similar at ages 45-49, 50-54 years

SAN ANTONIO — The increased prevalence of advanced adenoma and clinically significant serrated polyps was similar among age groups onREAD MORE ›

Posted in News

Ambient light could improve end-of-day adenoma detection

SAN ANTONIO — Performing colonoscopies in a room with ambient light could improve the decrease in adenoma detection rate thatREAD MORE ›

Posted in News

Healio Disruptive Innovators ‘On the Rise’ at ACG

During this year’s American College of Gastroenterology Annual Meeting in San Antonio, I had the honor of hosting the secondREAD MORE ›

Posted in News

Healio Disruptive Innovators at ACG 2019

Healio Gastroenterology and Liver Disease unveiled its second annual Disruptive Innovators Awards recipients at the American College of Gastroenterology AnnualREAD MORE ›

Posted in News

Healio Disruptive Innovators

Healio Disruptive Innovators Awards attendees networked with colleagues and took selfies with their peers.Read More

Posted in News

And Your 2019 Healio Disruptive Innovators Are …

This award goes to a physician or institution that changed the face of the gastroenterology practice. The awardee is seenREAD MORE ›

Posted in News

FDA approves Givlaari, first treatment for acute hepatic porphyria

The FDA approved Givlaari for the treatment of adults with acute hepatic porphyria, a rare genetic disorder that leads toREAD MORE ›

Posted in News

Weight parameters impact mortality in colorectal cancer

SAN ANTONIO — Obesity and underweight were associated with worse colorectal cancer outcomes, recurrence and mortality, compared with normal weight,READ MORE ›

Posted in News

Dicerna, Novo Nordisk partner to develop novel liver disease therapies

Dicerna Pharmaceuticals and Novo Nordisk announced an agreement to develop RNA interference therapies for liver-related cardiometabolic diseases, according to aREAD MORE ›

Posted in News

Archives

Categories